Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC

被引：0

作者：

Mohorcic, K. ^{[1
]}

Janzic, A. ^{[2
]}

Janzic, U. ^{[1
]}

Rot, M. ^{[3
]}

Kern, I. ^{[3
]}

机构：

[1] Univ Clin Golnik, Med Oncol Unit, Golnik, Slovenia

[2] Jazmp, Ljubljana, Slovenia

[3] Univ Clin Golnik, Dept Pathol, Golnik, Slovenia

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

EGFR mutations; osimertinib; NSCLC;

D O I：

10.1016/j.jtho.2019.08.1165

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.14-14

引用

页码：S557 / S558

页数：2

共 50 条

[1] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
Remon, Jordi
Caramella, Caroline
Joelet, Cecile
Lacroix, Ludovic
Lawson, Andrew
Smalley, Sarah
Howarth, Karen
Gale, Davina
Rosenfeld, Nitzan
Green, Emma
Plagnol, Vincent
Planchard, David
Bluthgen, Maria
Gazzah, Annas
Pannet, Chloe
Nicotra, Claudio
Soria, Jean-Charles
Besse, Benjamin
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
[2] Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
Watanabe, Kana
Saito, Ryota
Miyauchi, Eisaku
Nagashima, Hiromi
Nakamura, Atsushi
Sugawara, Shunichi
Tanaka, Nobuyuki
Terasaki, Hiroshi
Fukuhara, Tatsuro
Maemondo, Makoto
[J]. CANCERS, 2023, 15 (17)
[3] Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation
Ma, W.
Gong, J.
Shan, J.
Lewis, D.
Xiao, W.
Hung, J.
Moore, E. H.
Zhang, Y.
Mans, N. Z.
Welborn, J.
Lam, K. S.
Li, T.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1863 - S1864
[4] Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report
Thanasombunsukh, K.
Chamnongprasatporn, B.
Chiravirakul, P.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S649 - S650
[5] CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC
Paz-Ares, L.
Planchard, D.
Yang, J. C.
Lee, K.
Garrido, P.
Park, K. K.
Kim, J.
Lee, D. H.
Mao, H.
Chao, B.
Yu, H.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S453 - S454
[6] Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
Schmid, S.
Klingbiel, D.
Aeppli, S.
Britschgi, C.
Gautschi, O.
Pless, M.
Rothschild, S.
Wannesson, L.
Janthur, W.
Foerbs, D.
Demmer, I.
Jochum, W.
Fruth, M.
[J]. LUNG CANCER, 2019, 130 : 149 - 155
[7] Activation of IGF1R confers acquired resistance to osimertinib in EGFR-mutant NSCLC with T790M mutation
Hayakawa, Daisuke
Takahashi, Fumiyuki
Tajima, Ken
Mitsuishi, Yoichiro
Nakamura, Ikuko
Winardi, Wira
Shirai, Yukina
Miyashita, Yosuke
Yamada, Tomoko
Miura, Keita
Torasawa, Masahiro
Matsuda, Hironari
Asao, Tetsuhiko
Shukuya, Takehito
Takahashi, Kazuhisa
[J]. CANCER SCIENCE, 2022, 113 : 1060 - 1060
[8] Longitudinal disease monitoring with ctDNA during osimertinib treatment in EGFR T790M positive NSCLC patients (WJOG8815L)
Kato, Terufumi
Sakai, Kazuko
Takahama, Takayuki
Shimokawa, Mototsugu
Azuma, Koichi
Takeda, Masayuki
Okamoto, Isamu
Daga, Haruko
Teraoka, Shunsuke
Takahashi, Toshiaki
Ohira, Tatsuo
Yokoyama, Toshihide
Yamamoto, Nobuyuki
Nakagawa, Kazuhiko
Nishio, Kazuto
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S323 - S323
[9] Predictive factors and prognostic significance of T790M mutation in patients with EGFR-mutant NSCLC
Hwang, Ji An
Choi, Chang-Min
Lee, Jae Cheol
[J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50
[10] Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma
Su, Kang-Yi
Tseng, Jeng-Sen
Liao, Keng-Mao
Yang, Tsung-Ying
Chen, Kun-Chieh
Hsu, Kuo-Hsuan
Yang, Pan-Chyr
Yu, Sung-Liang
Chang, Gee-Chen
[J]. PLOS ONE, 2018, 13 (11):

← 1 2 3 4 5 →